April 10 (Reuters) - Swiss contract drugmaker PolyPeptide Group AG is attracting potential takeover interest from private equity firms including EQT AB and KKR & Co., Bloomberg News reported on Friday
PolyPeptide Group Attracts Interest from EQT, KKR and Advent for Takeover
Private Equity Interest in PolyPeptide Group
April 10 (Reuters) - Swiss contract drugmaker PolyPeptide Group AG is attracting potential takeover interest from private equity firms including EQT AB and KKR & Co., Bloomberg News reported on Friday, citing people with knowledge of the matter.
Key Developments and Interested Parties
Here are some details:
Advent's Acquisition Considerations
• Advent has also been studying a possible acquisition of PolyPeptide, the report said.
Potential Collaboration with Frederik Paulsen Jr.
• Any buyout firm pursuing a take-private deal could seek to collaborate with Swedish businessman Frederik Paulsen Jr., PolyPeptide's billionaire controlling shareholder, according to Bloomberg.
Market Performance and Valuation
• Shares of PolyPeptide have risen nearly 20% this year, increasing the company's market value to about 1 billion Swiss francs ($1.3 billion).
Deal Status and Company Responses
Ongoing Deliberations
• Deliberations are ongoing and there’s no certainty they will lead to a transaction, according to the report.
Statements from Involved Parties
Private Equity Companies' Response
• The private equity companies declined to comment, Bloomberg said, while a spokesperson for PolyPeptide told the news agency that the company remained focused on executing its strategic plan.
(Reporting by Hyunsu Yim in Barcelona; Editing by Kirsten Donovan)
